In October 2022, Smartz won the Kerrin Rennie Award for Excellence in Medical Technology – Improving Quality of Life. The award was established to recognise and profile the innovative and extraordinary contribution of medical technology in improving health outcomes of Australian patients.
Smartz monitors patient wellness including 2 significant issues affecting the elderly in residential aged care facilities; incontinence and pressure injuries.
Smartz also helps efficiency of staff time by reducing unnecessary diaper checks whilst also significantly reducing the invasive manual practices currently used to check when diapers need changing.
There was also a potential reduction in the number of diaper changes by changing the diaper only when really needed thus saving time, and improving toileting routines. These benefits may result in lower overall cost, fewer hospital admissions for UTIs, less waste, and more significantly, better individualised care.
Clinical study results have shown that the time residents are left in wet diapers significantly reduces when carers are alerted when the diaper has reached capacity. This reduces the risk of incontinence associated dermatitis (IAD) and UTIs.
Neina Fahey from the Medical Technology Association of Australia (MTAA) spoke with Peta Jurd, Smartz AG Commercial Director about winning the award.
-
Targeted National Lung Cancer Screening Program commences in 2025
In February 2025, Australian Health Journal spoke with Mark Brooke, Chief Executive Officer of Lung Foundation Australia, at the 10th Australian Lung Cancer Conference in Adelaide, on the upcoming commencement of the National Lung Cancer Screening Program (NLCSP)
-
Making clinical trials participant friendly
Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
The Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.
-
Developing the nation’s first Health and Medical Research Strategy
Professor Steve Wesselingh serves as the CEO of NHMRC, having initially trained as an infectious diseases doctor. His career includes prominent roles such as Head of the Infectious Diseases Unit at the Alfred Hospital, Director of the Burnett, Dean of Medicine at Monash University, and the inaugural Director of SAHMRI. Under his leadership, NHMRC plays a critical role in funding health and medical research, allocating approximately a billion dollars annually to investigator-led projects, clinical trials, and various strategic initiatives. NHMRC also collaborates internationally with organisations such as the MRC and the EU, and manages grant allocation for the MRFF, which distributes $650 million each year.
